In-Vitro Diagnostic Substance Manufacturing federal obligations in FY2024

In-Vitro Diagnostic Substance Manufacturing crossed with FY2024

NAICS 325413 and fiscal year 2024 share one yearlyTrend cell. $1,567,243,347.88 is the USAspending.gov obligation sum on the row that carries both tags. It is not In-Vitro Diagnostic Substance Manufacturing's nationwide all-year total of $1,876,000,543.48, not every federal dollar coded to FY2024, and not an outlay register. The packet does not split reagents from kits, or contract from assistance. 5,683 is an industry-extract action count: modifications and repeat awards add rows across years. Unique recipients are unpublished. This cell is not a test-kit catalog, a lot-release log, or a named-manufacturer roster.

The headline $1,567,243,347.88 sits beside an industry-wide obligation total of $1,876,000,543.48; the 83.5% share is arithmetic on those two packet facts, not a ranking of fiscal years as winners or losers. Obligations are not outlays. Do not convert 325413 into a named-manufacturer roster. Recipients stay unpublished.

How USAspending codes In-Vitro Diagnostic Substance Manufacturing in FY2024

USAspending labels NAICS 325413 as In-Vitro Diagnostic Substance Manufacturing. That code produced $1,567,243,347.88 when crossed with fiscal year 2024. The industry-wide 325413 hub does not require a FY2024 filter. The year hub does not require In-Vitro Diagnostic Mfg. Only this tie applies both filters. The packet does not split reagents from kits, or contract from assistance. FY2024 is a completed federal fiscal year in ordinary usage, but later ingests can still restate obligations. This page reports the packet figure.

Correlation is not causation: FY2024 did not produce $1,567,243,347.88 merely by existing as a large or small budget year. The join is 325413 × FY2024 only. This cell is not a test-kit catalog, a lot-release log, or a named-manufacturer roster. Do not invent contractors or award recipients to fill the gap. Campaign donations on FEC tables do not fund this USAspending cell; the datasets are separate. Five thousand six hundred eighty-three industry-extract awards are the 325413 action count across years, not a FY2024 lot-release census.

Award records on NAICS 325413 versus the FY2024 dollar cell

5,683 is the In-Vitro Diagnostic Substance Manufacturing award-record count published with the industry extract, not a count of FY2024 instruments. Dividing $1,567,243,347.88 by 5,683 would mix a one-year dollar total with a multi-year row count, so this page does not publish that ratio as a typical invoice. Unique recipients are unpublished. Modifications and multi-year vehicles can add lines without adding vendors. Five thousand six hundred eighty-three industry-extract awards are the 325413 action count across years, not a FY2024 lot-release census. Later USAspending ingests can still restate FY2024 obligations without changing the join keys.

A thick parent file makes a program split tempting; the packet still does not supply one. A thin parent file makes a named-facility story tempting; the packet still does not name facilities or contractors. 83.5% of $1,876,000,543.48 is the year share on this packet, not a performance score.

Commitment totals versus cash paid

USAspending.gov records an obligation when the federal government commits funds on an award. $1,567,243,347.88 is that kind of sum for In-Vitro Diagnostic Substance Manufacturing in FY2024. Later deobligations, recoveries, or payment schedules can change what leaves the Treasury without this join rewriting itself into a cash register. Assistance and contract awards can share the same NAICS rollup; this packet does not split them. Net obligations can include downward adjustments. This page reports $1,567,243,347.88 as given.

Keeping both sides of the 325413 × FY2024 pair

Cite USAspending.gov: In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) obligated $1,567,243,347.88 in FY2024. Name In-Vitro Diagnostic Substance Manufacturing and FY2024 together. Keep the obligation word. If /industries/325413/ or /fiscal-years/2024/ has refreshed, prefer the live hub over this snapshot for current rows. The pair is not a test-kit catalog, a lot-release log, or a named-manufacturer roster. 83.5% of $1,876,000,543.48 is the industry share on this packet, not a budget score. /industries/ lists other industries; /ties/ indexes other pairs.

Share, extract count, and what they are not

Five thousand six hundred eighty-three industry-extract awards are the 325413 action count across years, not a FY2024 lot-release census. In-vitro diagnostic substances are a manufacturing code, not medical laboratories (621511) in this slice. Keep 325413 on FY2024. A reader who quotes 5,683 as unique companies in FY2024 has left the packet. A reader who treats 83.5% as a hardship or success ranking has added a score the table does not carry. Prefer /industries/325413/ and /fiscal-years/2024/ if the live tables moved. Do not convert 325413 into a named-manufacturer roster. Recipients stay unpublished.

This snapshot holds $1,567,243,347.88 on the yearlyTrend row and 5,683 on the industry extract. /ties/ is the index, not an addend. Obligations are not outlays. Correlation is not causation. A reader who only quotes $1,567,243,347.88 without FY2024 and NAICS 325413 has dropped a join side.

Questions

How much In-Vitro Diagnostic Mfg spending is obligated in FY2024?

USAspending.gov lists $1,567,243,347.88 in In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) obligations for FY2024. That yearlyTrend amount is 83.5% of the industry's $1,876,000,543.48 extract-wide total. It is an obligation join, not an outlay and not every federal dollar in FY2024. Unique recipients are unpublished.

Is $1,567,243,347.88 the entire In-Vitro Diagnostic Mfg USAspending total?

No. NAICS 325413's extract-wide total is $1,876,000,543.48. FY2024 is 83.5% of that book. Other fiscal-year rows for the same industry are separate cells. Do not add /industries/325413/ into this join. 5,683 award records stay on the industry extract, not on this yearlyTrend row.

Is $1,567,243,347.88 cash already paid in FY2024?

No. Obligations are commitments recorded on USAspending.gov awards. Outlays — money that actually left the Treasury — are a different concept and are not this packet's headline. Treating $1,567,243,347.88 as checks already cleared in FY2024 confuses those terms. Prefer the live industry and year hubs if the tables moved.

Is $1,567,243,347.88 the nationwide In-Vitro Diagnostic Mfg total?

No. $1,567,243,347.88 is the FY2024 yearlyTrend slice of NAICS 325413 only. Industry-wide In-Vitro Diagnostic Mfg is $1,876,000,543.48 on /industries/325413/ without this year filter. 83.5% describes this join. Outlays are unpublished. Source is USAspending.gov. USAspending.gov remains the source for NAICS 325413 in FY2024.